ExTRACT-TIMI 25 trial: clarifying the role of enoxaparin in patients with ST-elevation myocardial infarction receiving fibrinolysis

References

• Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction. Design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis in Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am. Heart J.149(2), 217–226 (2005).
   PubMed Web of Science ®Google Scholar
• Gibson CM, Karha J, Murphy SA et al. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J. Am. Coll. Cardiol.42(1), 7–16 (2003).
   PubMed Web of Science ®Google Scholar
• Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med.354(14), 1477–1488 (2006).
   PubMed Web of Science ®Google Scholar
• The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators N. Engl. J. Med.329(22), 1615–1622 (1993).
   PubMed Web of Science ®Google Scholar
• Thompson PL, Aylward PE, Federman J et al. A randomized comparison of intravenous heparin with oral aspirin and dipyridamole 24 hours after recombinant tissue-type plasminogen activator for acute myocardial infarction. National Heart Foundation of Australia Coronary Thrombolysis Group. Circulation83(5), 1534–1542 (1991).
   PubMed Web of Science ®Google Scholar
• Girolami B, Girolami A. Heparin-induced thrombocytopenia: a review. Semin. Thromb. Hemost.32(8), 803–809 (2006).
   PubMed Web of Science ®Google Scholar
• Antman EM, Louwerenburg HW, Baars HF et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 Trial. Circulation105(14), 1642–1649 (2002).
   PubMed Web of Science ®Google Scholar
• Ross AM, Molhoek P, Lundergan C et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation104(6), 648–652 (2001).
   PubMed Web of Science ®Google Scholar
• Baird S, Menown I, McBride S, Trouton T, Wilson C. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur. Heart J.23, 627–632 (2002).
   PubMed Web of Science ®Google Scholar
• Eikelboom JW, Quinlan DJ, Mehta SR, Turpie AG, Menown IB, Yusuf S. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation112(25), 3855–3867 (2005).
   PubMed Web of Science ®Google Scholar
• The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet358(9282), 605–613 (2001).
   PubMed Web of Science ®Google Scholar
• Wallentin L, Goldstein P, Armstrong PW et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation108(2), 135–142 (2003).
   PubMed Web of Science ®Google Scholar
• Armstrong PW, Chang WC, Wallentin L et al. Efficacy and safety of unfractionated heparin versus enoxaparin: a pooled analysis of ASSENT-3 and -3 PLUS data. CMAJ174(10), 1421–1426 (2006).
   PubMedGoogle Scholar
• Giraldez R, Nicolau J, Corbalan R et al. Enoxaparin is superior to unfractionated heparin in patients with ST elevation myocardial infarction undergoing fibrinolysis regardless of choice of lytic: an ExTRACT-TIMI 25 analysis. Eur. Heart J.28(13), 1556–1573 (2007).
   Google Scholar
• Bijsterveld NR, Peters RJ, Murphy SA, Bernink PJ, Tijssen JG, Cohen M. Recurrent cardiac ischemic events early after discontinuation of short-term heparin treatment in acute coronary syndromes: results from the Thrombolysis in Myocardial Infarction (TIMI) 11B and Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q-Wave Coronary Events (ESSENCE) studies. J. Am. Coll. Cardiol.42(12), 2083–2089 (2003).
   PubMed Web of Science ®Google Scholar
• White HD, Braunwald E, Murphy SA et al. Enoxaparin vs unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction in elderly and younger patients: results from ExTRACT-TIMI 25. Eur. Heart J.28(9), 1066–1071 (2007).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Cannon CP, Gibson CM et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N. Engl. J. Med.352(12), 1179–1189 (2005).
   PubMed Web of Science ®Google Scholar
• Chen ZM, Jiang LX, Chen YP et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet366(9497), 1607–1621 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Montalescot G et al. Angiographic and clinical outcomes in patients receiving low-molecular-weight heparin versus unfractionated heparin in ST-elevation myocardial infarction treated with fibrinolytics in the CLARITY-TIMI 28 trial. Circulation112(25), 3846–3854 (2005).
   PubMed Web of Science ®Google Scholar
• Sabatine MS, Morrow DA, Dalby A et al. Efficacy and safety of enoxaparin versus unfractionated heparin in patients with ST-segment elevation myocardial infarction also treated with clopidogrel. J. Am. Coll. Cardiol.49(23), 2256–2263 (2007).
   PubMed Web of Science ®Google Scholar
• Gibson CM, Murphy SA, Montalescot G et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J. Am. Coll. Cardiol.49(23), 2238–2246 (2007).
   PubMed Web of Science ®Google Scholar